Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1206 participants.

Also called NCT05283356

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,206 participants (planned count) (from the registry)
Sponsor
Fundacin Biomedica Galicia Sur (from the registry)
Registry
  • NCT NCT05283356
  • EudraCT 2021-003927-13
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05283356. Randomized; no masking; primary purpose treatment. Start 2022-01-21 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
Acronym
REAC-TAVI2
Condition
Severe Aortic Valve Stenosis
Condition
Aortic Valve Stenosis
Condition
Transcatheter Aortic Valve Implantation (TAVI)
Intervention (Drug)
Ticagrelor 60mg
Lead sponsor
Fundacin Biomedica Galicia Sur (class: other)

Record details

Record id
cardio:ct-nct05283356
Content hash
ed61f4a297598d1cf3e1cd101a080e322e192c6803c8e7ebba8f93e4c0321b24